22.53
price down icon0.40%   -0.09
pre-market  Vorhandelsmarkt:  22.50   -0.03   -0.13%
loading
Schlusskurs vom Vortag:
$22.62
Offen:
$22.55
24-Stunden-Volumen:
2.08M
Relative Volume:
1.00
Marktkapitalisierung:
$3.80B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
125.17
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+5.33%
1M Leistung:
+5.68%
6M Leistung:
+56.13%
1J Leistung:
+52.85%
1-Tages-Spanne:
Value
$22.05
$22.92
1-Wochen-Bereich:
Value
$21.07
$23.05
52-Wochen-Spanne:
Value
$13.40
$26.65

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Firmenname
Acadia Pharmaceuticals Inc
Name
Telefon
858-558-2871
Name
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Name
Mitarbeiter
654
Name
Twitter
@acadiapharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
ACAD's Discussions on Twitter

Vergleichen Sie ACAD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
22.53 3.82B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.25B 4.58B 3.56B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-21 Eingeleitet Citigroup Buy
2025-05-21 Hochstufung Deutsche Bank Hold → Buy
2025-02-11 Eingeleitet Deutsche Bank Hold
2025-01-03 Herabstufung Guggenheim Buy → Neutral
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-03-12 Herabstufung Mizuho Buy → Neutral
2024-03-12 Bestätigt Needham Buy
2024-01-30 Eingeleitet Robert W. Baird Outperform
2024-01-24 Hochstufung Needham Hold → Buy
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-12-14 Herabstufung Deutsche Bank Buy → Hold
2023-12-13 Eingeleitet Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-11-06 Hochstufung Mizuho Neutral → Buy
2023-10-17 Eingeleitet UBS Buy
2023-10-10 Hochstufung JP Morgan Neutral → Overweight
2023-01-03 Hochstufung Guggenheim Neutral → Buy
2022-11-04 Herabstufung Goldman Neutral → Sell
2022-11-01 Eingeleitet Loop Capital Hold
2022-08-08 Herabstufung Citigroup Buy → Neutral
2022-08-05 Herabstufung Citigroup Buy → Neutral
2022-06-21 Herabstufung Jefferies Buy → Underperform
2022-06-16 Hochstufung Jefferies Hold → Buy
2022-03-16 Hochstufung Canaccord Genuity Hold → Buy
2022-02-09 Hochstufung H.C. Wainwright Neutral → Buy
2022-01-05 Hochstufung Citigroup Neutral → Buy
2021-12-21 Herabstufung Guggenheim Buy → Neutral
2021-11-01 Hochstufung Guggenheim Neutral → Buy
2021-10-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-23 Fortgesetzt Needham Hold
2021-06-10 Eingeleitet Berenberg Hold
2021-04-07 Herabstufung H.C. Wainwright Buy → Neutral
2021-04-06 Herabstufung Canaccord Genuity Buy → Hold
2021-04-06 Herabstufung Goldman Buy → Neutral
2021-04-06 Herabstufung Jefferies Buy → Hold
2021-04-06 Herabstufung Mizuho Buy → Neutral
2021-04-05 Herabstufung Raymond James Outperform → Mkt Perform
2021-03-10 Herabstufung BofA Securities Buy → Neutral
2021-03-09 Herabstufung Citigroup Buy → Neutral
2021-03-09 Herabstufung Guggenheim Buy → Neutral
2021-03-09 Bestätigt H.C. Wainwright Buy
2021-03-09 Herabstufung Raymond James Strong Buy → Outperform
2021-03-09 Herabstufung Stifel Buy → Hold
2020-12-16 Eingeleitet Mizuho Buy
2020-11-16 Hochstufung Raymond James Outperform → Strong Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-20 Eingeleitet Morgan Stanley Overweight
2020-07-07 Hochstufung Stifel Hold → Buy
2020-04-16 Eingeleitet Jefferies Buy
2020-03-31 Hochstufung Goldman Neutral → Buy
2020-03-06 Eingeleitet Citigroup Buy
2019-12-16 Eingeleitet Guggenheim Buy
2019-10-24 Eingeleitet Oppenheimer Perform
2019-10-01 Eingeleitet RBC Capital Mkts Outperform
2019-09-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-10 Hochstufung Canaccord Genuity Hold → Buy
2019-07-23 Bestätigt Needham Buy
2018-12-10 Eingeleitet Canaccord Genuity Hold
2018-09-21 Hochstufung Piper Jaffray Neutral → Overweight
2018-08-09 Bestätigt Stifel Hold
2018-08-07 Eingeleitet Stifel Hold
2018-08-06 Herabstufung Piper Jaffray Overweight → Neutral
2017-10-06 Fortgesetzt Goldman Neutral
Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

pulisher
Oct 29, 2025

ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Activity Recap & Precise Buy Zone Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Oct 29, 2025
pulisher
Oct 29, 2025

ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekers - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Why ACADIA Pharmaceuticals Inc. stock remains undervaluedMarket Sentiment Review & Community Trade Idea Sharing - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Allianz Asset Management GmbH Has $369,000 Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsRisk Management & Daily Growth Stock Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Understanding ACADIA Pharmaceuticals Inc.’s price movementJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

Acadia Pharmaceuticals (NASDAQ: ACAD) to Join UBS and Jefferies Healthcare Conferences - Stock Titan

Oct 28, 2025
pulisher
Oct 28, 2025

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire

Oct 28, 2025
pulisher
Oct 28, 2025

Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Is ACADIA Pharmaceuticals Inc. stock a top momentum play2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

How ACADIA Pharmaceuticals Inc. stock performs after earningsRecession Risk & Long-Term Safe Investment Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

How ACADIA Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Patterns & Reliable Volume Spike Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Real time alert setup for ACADIA Pharmaceuticals Inc. performanceIPO Watch & Long-Term Investment Growth Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is ACADIA Pharmaceuticals Inc. stock supported by strong fundamentalsMarket Risk Summary & Weekly Momentum Stock Picks - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Why ACADIA Pharmaceuticals Inc. stock is rated strong buyWeekly Volume Report & High Yield Equity Trading Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Advances Phase 2 Study of ACP-204 for Lewy Body Dementia Psychosis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic - Barchart.com

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Advances Study on Carbetocin Nasal Spray for Prader-Willi Syndrome - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Merger Talk: What catalysts could drive ACADIA Pharmaceuticals Inc. stock higherEntry Point & Fast Gaining Stock Strategy Reports - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Is ACADIA Pharmaceuticals Inc. reversing from oversold territoryEarnings Beat & Intraday High Probability Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.Jobs Report & Growth Focused Investment Plans - newser.com

Oct 27, 2025

Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$36.67
price up icon 0.71%
$90.18
price down icon 1.60%
$28.95
price down icon 0.62%
$103.35
price down icon 1.60%
biotechnology ONC
$314.85
price down icon 0.63%
$166.95
price up icon 1.00%
Kapitalisierung:     |  Volumen (24h):